EUCTR2006-003709-15-DK进行中（未招募）不适用
A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin (Pre- and Post Chemotherapy and Pre-Chemotherapy only) for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma (MM) Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 275
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Multiple myeloma (MM) subjects scheduled to receive high-dose Melphalan (200 mg/m2 if creatinine clearance = 30 mL/min or 140 mg/m2 if creatinine clearance < 30 mL/min), in a one day schedule (day -2) followed by autologous PBSCT (day 0)
- •Age = 18 years and = 70 years
- •BMI = 35
- •ECOG performance status = 2, or an ECOG status of 3 if the reason for a status of 3 is due exclusively due to MM (e.g. pathological fracture)
- •Adequate pulmonary function as measured by a corrected carbon monoxide (CO) diffusing capacity (DLCO) = 50% of predicted
- •Minimum of 2.0 x 106 CD34+ cells/kg collected for autologous transplantation
- •Adequate hematological function (ANC = 1.5 x 109/L and platelet count = 100 x 109/L)
- •Total bilirubin = 2 mg/dL
- •Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) = 4.0 x IULN
- •Negative serum or urine pregnancy test for women of child bearing potential within 14 days prior to enrolment
- •Each subject must give informed consent directly or through a legally acceptable representative before participating in any study specific procedure, or receiving any study medication
- •Cataract specific:
- •All subjects eligible for 20050219 will also be assessed for their eligibility for cataract
- •assessment procedures. If a subject is not eligible for cataract assessment procedures, or the site has a waiver from Amgen regarding cataract assessments, the subject may still be eligible for inclusion in the study but will be exempt from the cataract assessments.
- •Subjects at minimum with a baseline best corrected visual acuity (BCVA) of 20/40, (6/12 or 0.5 on the decimal scale) or better using the ETDRS chart in one eye
- •Subject at minimum with one eye with a natural, intact lens
- •Subject who has a LOCS III score at baseline of P < 1.0, C < 2.0 and NO < 2.0
- •(in at least one eye)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 239
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 42
排除标准
- •History of or concurrent malignancy other than MM, with the exception of curatively treated basal cell or squamous cell carcinoma of the skin, in situ cervical carcinoma, or other surgically cured malignancy, without evidence of disease for > 3 years
- •Prior treatment with palifermin, or other fibroblast or keratinocyte growth factors
- •(eg, KGF-2)
- •Prior autologous or allogeneic transplants
- •Currently active infection of oral mucositis
- •Oral abnormalities defined as baseline oral assessment of WHO grade > 0
- •Receiving dialysis
- •Twenty-eight days or less between receiving any other investigational drug or device and randomization into this study
- •Subject of child-bearing potential is evidently pregnant (eg, positive HCG test) or is breast feeding
- •Subject has not agreed to using adequate contraceptive precautions
- •Known to be sero-positive for human immunodeficiency virus (HIV), hepatitis B virus (HBSAg+), or hepatitis C virus (HCV)
- •Subject has known sensitivity to any of the products to be administered during dosing, including E coli-derived products
- •Subject has previously been treated on this study
- •Unwilling or unable to complete the patient-reported outcome questionnaires
- •Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures
- •Cataract specific:
- •History of cataract surgery in both eyes
- •Incapable of being responsive to midriatic agents (minimum of approximately a 6
- •mm pupil required)
- •History of other ocular disease leading to visual loss (e.g., macular degeneration,
- •glaucoma, corneal disease) that would make assessment of visual status difficult
- •Subject is scheduled to undergo cataract surgery
- •Subject with any disease, that in the opinion of the ophthalmologist, could
- •adversely effect the subject’s vision during the course of the study
研究者
相似试验
招募中
2 期
To study the effect of Turmeric-Boswellia combination in females with menstrual pain.CTRI/2024/07/070121Arjuna Natural Private Limited
进行中（未招募）
不适用
A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin (Pre- and Post Chemotherapy and Pre-Chemotherapy only) for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma (MM) Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)Oral Mucositis Induced by High Dose ChemotherapyCataract development associated with palifermin administrationMedDRA version: 8.1Level: LLTClassification code 10028130Term: Mucositis oralMedDRA version: 9.1Level: LLTClassification code 10007739Term: CataractEUCTR2006-003709-15-DEBiovitrum AB (publ)275
进行中（未招募）
不适用
A study comparing two different dosing regimens of palifermin (beforeand after chemotherapy versus before chemotherapy) with placebo onthe effect of reducing oral mucositis in patients with multiple myelomawho have been given treatment with high dose melphalan followed bystem cell transplantation.Oral Mucositis Induced by High Dose ChemotherapyCataract development associated with palifermin administrationMedDRA version: 14.0Level: LLTClassification code 10028130Term: Mucositis oralSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 14.0Level: PTClassification code 10007739Term: CataractSystem Organ Class: 10015919 - Eye disordersEUCTR2006-003709-15-ATSwedish Orphan Biovitrum AB (publ)275
进行中（未招募）
不适用
A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin Pre- and Post Chemotherapy and Pre-Chemotherapy only for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma MM Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation PBSCT - EU PMC in Heme TxMieloma Multiple SubjectMedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2006-003709-15-ITAMGEN S.P.A.275
进行中（未招募）
不适用
A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin (Pre- and Post Chemotherapy and Pre-Chemotherapy only) for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma (MM) Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)Oral Mucositis Induced by High Dose ChemotherapyCataract development associated with palifermin administrationMedDRA version: 8.1Level: LLTClassification code 10028130Term: Mucositis oralMedDRA version: 9.1Level: LLTClassification code 10007739Term: CataractEUCTR2006-003709-15-HUBiovitrum AB (publ)